Quality of life in goserelin-treated versus cyclophosphamide + methotrexate + fluorouracil-treated premenopausal and perimenopausal patients with node-positive, early breast cancer: The Zoladex Early Breast Cancer Research Association Trialists Group

Journal of Clinical Oncology

Volumn 21, Issue 24, 2003, Pages 4510-4516

  De Haes, Hanneke ^a   Olschewski, M ^a   Kaufmann, M ^a   Schumacher, M ^a   Jonat, W ^a   Sauerbrei, W ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; FLUOROURACIL; GOSERELIN; METHOTREXATE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; CMF REGIMEN;

ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RESEARCH; CLIMACTERIUM; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DISEASE COURSE; DISTRESS SYNDROME; HUMAN; LYMPH NODE; MAJOR CLINICAL STUDY; MEDICAL SOCIETY; PREMENOPAUSE; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; ADULT; BREAST TUMOR; FACTORIAL ANALYSIS; FEMALE; LYMPH NODE METASTASIS; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY;

ADULT; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CLIMACTERIC; CYCLOPHOSPHAMIDE; FACTOR ANALYSIS, STATISTICAL; FEMALE; FLUOROURACIL; GOSERELIN; HUMANS; LYMPHATIC METASTASIS; METHOTREXATE; MIDDLE AGED; PREMENOPAUSE; QUALITY OF LIFE; QUESTIONNAIRES;

EID: 1542438694     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.11.064     Document Type: Article

References (19)

1. Jonat W, Kaufmann M, Sauerbrei W, et al: Goserelin versus CMF as adjuvant therapy in premenopausal patients with node-positive breast cancer: the ZEBRA study. J Clin Oncol 20:4628-4635, 2002
2. Hurny C, Bernhard J, Coates A: Quality of life assessment in the International Breast Cancer Study Group: Past, present, and future. Recent Results Cancer Res 152:390-395, 1998
3. Shapiro CL, Recht A: Side effects of adjuvant treatment of breast cancer. N Engl J Med 344:1997-2008, 2001
4. Jonat W: Zoladex versus adjuvant therapy in pre/peri-menopausal breast cancer: tolerability and amenorrhoea comparisons. Proc Am Soc Clin Oncol 19:87, 2000 (abstr 333)
5. Bines J, Oleske DM, Cobleigh MA: Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 14:1718-1729, 1996
6. Goodwin PJ, Ennis M, Pritchard K, et al: Risk of menopause during the first year after breast cancer diagnosis. J Clin Oncol 17:2365-2370, 1999
7. Blamey RW, Jonat W, Kaufmann M, et al: Zoladex depot in the treatment of premenopausal advanced breast cancer. Eur J Cancer 28:810-814, 1992
8. Fallowfield J-J, Leaity SK, Howell A, et al: Assessment of quality of life in women undergoing hormonal therapy for breast cancer: Validation of an endocrine symptom subscale for the FACT-B. Breast Cancer Res Treat 55:189-199, 1999
9. Kaufmann M, von Minckwitz G: The emerging role of hormonal ablation as adjuvant therapy in node + and node - pre-/perimenopausal patients. Breast 10:123-129, 2001 (suppl 3)
10. Bonadonna G, Brusamolino E, Valagussa P, et al: Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 294:405-410, 1976
11. de Haes JCJM, Van Knippenberg FCE, Neijt JP: Measuring psychological and physical distress in cancer patients: Structure and application of the Rotterdam Symptom Check List. Br J Cancer 62:1034-1038, 1990
12. Tempelaar R, de Haes JCJM, de Rutter JH, et, al: The social experiences of cancer patients under treatment: A comparative study. Soc Sci Med 29:635-642, 1989
13. Hurny C, Bernhard J, Gelber RD, et al: Quality of life measures for patients receiving adjuvant therapy for breast cancer: An international trial-The International Breast Study Group. Eur J Cancer 28:118-124, 1992
14. de Haes JCJM, Olschewski M, Fayers P, et al: Measuring the quality of life of cancer patients with the Rotterdam Symptom Checklist (RSCL): A Manual. Groningen, the Netherlands, Northern Center for Healthcare Research, University of Groningen, 1996
15. de Haes JCJM, De Ruiter JH, Tempelaar R, et al: The distinction between affect and cognition in the quality of life of cancer patients: Sensitivity and stability. Qual Life Res 1:315-322, 1992
16. de Haes JCJM, Olschewski M: Quality of life assessment in a cross-cultural context: Use of the Rotterdam Symptom Checklist in a multinational randomized trial comparing CMF with Zoladex (Goserelin) treatment in early breast cancer. Ann Oncol 9:745-750, 1998
17. Stiggelbout AM, de Haes JCJM: Patient preference for cancer therapy: An overview of measurement approaches. J Clin Oncol 19:220-230, 2001
18. Berglund G, Nystedt M, Bolund C, et al: Effect of endocrine treatment on sexuality in premenopausal breast cancer patients: A prospective randomized study. J Clin Oncol 19:2788-2796, 2001
19. Sloan J: Asking the obvious questions regarding patient burden. J Clin Oncol 20:4-6, 2002